[SCHEDULE 13G] Microbot Medical, Inc. SEC Filing

Rhea-AI Filing Summary

The Vanguard Group filed a Schedule 13G indicating that, as of 30 Jun 2025, it beneficially owns 2,050,638 shares of Microbot Medical Inc. (MBOT), equal to 5.63 % of the company’s outstanding common stock.

Vanguard reports no sole or shared voting power, suggesting that voting rights remain with underlying clients. It does, however, hold dispositive authority over nearly all shares (2,030,667 sole; 19,971 shared), allowing it to sell the position on clients’ behalf.

• Crossing the 5 % threshold triggers this initial passive disclosure under Rule 13d-1(b).
• The stake is held in the ordinary course of business; Vanguard states no intent to influence control.
• Ownership is spread across multiple Vanguard-managed funds and accounts, with no single client exceeding 5 %.

The filing enhances MBOT’s institutional ownership profile but signals limited governance influence because Vanguard retains dispositive—not voting—control.

Positive

• Vanguard now holds 5.63 % of MBOT, boosting the company’s institutional ownership profile
• The presence of a reputable asset manager may improve share liquidity and visibility among index-tracking investors

Negative

• Vanguard retains no voting power, limiting any potential governance support for shareholders
• The passive nature of the filing signals no strategic interest or takeover intentions

Insights

Securities Analyst

TL;DR: Vanguard’s 5.63 % passive stake adds institutional validation to MBOT shares.

Vanguard crossing the 5 % threshold puts a well-known index manager on MBOT’s cap table, potentially improving liquidity and investor attention. Although the firm lacks voting power, its ability to dispose of >2 M shares shows confidence in handling client assets in a micro-cap name. The disclosure is positive for market perception but does not alter fundamentals or control.

Corporate Governance Expert

TL;DR: Zero voting rights mean negligible governance impact despite sizable holding.

The 13G confirms Vanguard’s position is strictly passive and non-influential. With neither sole nor shared voting authority, Vanguard cannot sway board matters, proxy contests, or strategic decisions. Investors should view this as a transparency event rather than a catalyst for corporate change.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Microbot Medical Inc

(Name of Issuer)

Common Stock

(Title of Class of Securities)

59503A204

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 59503A204

1

Names of Reporting Persons

The Vanguard Group

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

PENNSYLVANIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,030,667.00
8	Shared Dispositive Power 19,971.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,050,638.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.63 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Microbot Medical Inc
(b)	Address of issuer's principal executive offices: 175 Derby Street, Suite 27/1, Hingham, MA, 02043
Item 2.
(a)	Name of person filing: The Vanguard Group
(b)	Address or principal business office or, if none, residence: 100 Vanguard Blvd., Malvern, PA 19355
(c)	Citizenship: PA
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 59503A204
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 2050638
(b)	Percent of class: 5.63 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 2030667
	(iv) Shared power to dispose or to direct the disposition of: 19971
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

The Vanguard Group

Signature:	Ashley Grim
Name/Title:	Head of Global Fund Administration
Date:	07/29/2025

FAQ

What percentage of Microbot Medical (MBOT) shares does Vanguard own?

5.63 % of the outstanding common stock, as disclosed in the Schedule 13G.

How many MBOT shares are beneficially owned by The Vanguard Group?

A total of 2,050,638 shares as of 30 June 2025.

Does Vanguard have voting power over its MBOT shares?

No. The filing reports 0 sole and 0 shared voting power.

Why did Vanguard file a Schedule 13G for MBOT?

Its stake exceeded the 5 % ownership threshold, requiring passive disclosure under SEC Rule 13d-1(b).

When was the Schedule 13G event date and signature date?

Event date: 06/30/2025; filing signed on 07/29/2025 by Ashley Grim.